교수진

허재성

허재성 교수

방사선종양학교실

메일
nahero@ajou.ac.kr
전화
031-219-5337
홈페이지

연구분야

의료와 IT의 융합 연구
1) 두경부암 AI 플랫폼
- 두경부암 학습용 데이터 구축 (10,000장이상)
- 두경부암 판독 모델 개발
- 치료 반응 예측 모델 개발
2) 빅데이터
- 보건 의료 빅데이터 분석
건강보험 심사 평가원 데이터 / 건강 보험 공단 데이터
- 표준화된 EMR data 분석
3) 디지털 헬스
- 모바일 앱 개발 및 활용 연구
유방 자가검진 / 지역암센터 기반의 암 생존자 관리 플랫폼

학력

2008의학사, 중앙대

2013의학석사, 아주대

2017의학박사, 아주대

경력

2016-2018 아주의대 방사선종양학교실 임상강사

2018-2021 아주의대 방사선종양학교실 연구조교수

2021-現 아주의대 방사선종양학교실 조교수

㈜디알랩 대표이사

대표실적

[2013] Radiation Oncology Journal Parotid gland sparing effect by computed tomography-based modified lower field margin in whole brain radiotherapy

[2013] Radiation Oncology Can initial diagnostic PET-CT aid to localize tumor bed in breast cancer radiotherapy: Feasibility study using deformable image registration

[2013] Healthcare Informatics Research Effects of a smartphone application on breast self-examination: A feasibility study

[2013] Journal of gynecologic oncology Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases

[2014] Radiotherapy and oncology Prognostic implication of pulmonary function at the beginning of postoperative radiotherapy in non-small cell lung cancer. Radiotherapy and oncology

[2014] Radiation Oncology Journal CT-based quantitative evaluation of radiation-induced lung fibrosis: A study of interobserver and intraobserver variations

[2016] International Journal of Radiation Oncology Biology Physics Radiation Therapy-First Strategy after Surgery with or Without Adjuvant Chemotherapy in Stage IIIA-N2 Non-Small Cell Lung Cancer

[2016] Cancer research and treatment Sustaining blood lymphocyte count during preoperative chemoradiotherapy as a predictive marker for pathologic complete response in locally advanced rectal cancer

[2016] Radiation Oncology Journal tumor response according to the count of peripheral blood lymphocyte subpopulations during preoperative chemoradiotherapy in locally advanced rectal cancer

[2016] Radiation Oncology Journal Comparison of concurrent chemoradiotherapy versus sequential radiochemotherapy in patients with completely resected non-small cell lung cancer